Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to provide insights that address...

Lunsumio® (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the pivotal phase I/II study...

Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of...

Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions Collaboration builds on commitment to advance personalised healthcare by helping to improve access to new...

WHO’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countries Since the beginning of the pandemic, more than one million...

Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet...